Business

MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research Analyst, on Monday, September 8, 2025 at 4:30p.m. ET at the H.C. Wainwright 27th Annual Global Investment Conference. A live webcast of the event will be accessible both here and on MediW

Mediwound Ltd.August 20, 20251
MediWound to Present at the H.C. Wainwright 27th Annual Global Investment Conference

About this update from Mediwound Ltd.

YAVNE, Israel, August 20, 2025 -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research Analyst, on Monday, September 8, 2025 at 4:30p.m. ET at the H.C. Wainwright 27 th Annual Global Investment Conference. A live webcast of the event will be accessible both here and on MediWound’s website, under the Events & Presentations page of the Investors section. About MediWound MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company focused on developing and commercializing enzymatic therapies for non-surgical tissue repair. The company’s FDA-approved biologic, NexoBrid ® , is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the U.S., European Union, Japan, and other international markets. MediWound is also advancing EscharEx ® , a late-stage investigational therapy for the debridement of chronic wounds. EscharEx has demonstrated clinical advantages over the leading enzymatic debridement product and targets a substantial global market opportunity. For more information visit  www.mediwound.com  and follow us on  LinkedIn . MediWound Contacts:                                                                        Hani Luxenburg                                                                        Daniel Ferry Chief Financial Officer                                                             Managing Director MediWound Ltd.                                                                        LifeSci Advisors, LLC [email protected]                                                                   [email protected] Media Contact: Ellie Hanson FINN Partners for MediWound [email protected] +1-929-588-2008

View stock analysis, news, and events for Mediwound Ltd.

MediWound Ltd.Equity Research AnalystNasdaqMDWDChief Executive Officertissue repairInvestment Conference

More from Mediwound Ltd.

All Mediwound Ltd. news →